HNSCC

Related by string. * * carcinoma HNSCC *

Related by context. All words. (Click for frequent words.) 75 prostate cancer CaP 74 pancreatic adenocarcinoma 72 prostate carcinoma 72 histologic subtype 71 nonmetastatic 71 colorectal adenoma 71 urothelial carcinoma 71 breast carcinoma 71 tumor histology 71 colorectal cancer CRC 71 MGUS 70 endometrial cancers 70 neoplasias 70 histological subtype 70 gastric carcinoma 70 ADPKD 70 PCNSL 70 colorectal carcinoma 70 differentiated thyroid 70 seminoma 70 prostate cancer PCa 70 nodal metastasis 70 epithelial ovarian cancer 69 ovarian carcinoma 69 gastric adenocarcinoma 69 distant metastasis 69 nonsmall cell lung cancer 69 tumor recurrence 69 advanced adenomas 69 advanced adenoma 69 poorer prognosis 69 PCa 69 recurrent glioblastoma multiforme 69 hepatocellular carcinomas 69 squamous cell lung cancer 69 invasive ductal 69 malignant neoplasm 69 serous ovarian cancer 69 papillary renal cell carcinoma 69 biochemical recurrence 69 T1DM 69 basal cell carcinoma BCC 69 urothelial cancer 68 medically inoperable 68 HER2 overexpression 68 epithelial tumors 68 atypical hyperplasia 68 colorectal tumors 68 nonmelanoma skin cancers 68 testicular germ cell 68 operable breast cancer 68 oropharyngeal cancer 68 premalignant 68 stage IIIB 68 MYCN amplification 68 HER2 positive cancers 68 KRAS mutations occur 68 esophageal squamous cell carcinoma 68 adenomatous polyps 68 lobular carcinoma 68 malignant pleural mesothelioma 68 skeletal metastases 68 clinically localized prostate 67 precursor lesions 67 CIN3 67 CIN2 + 67 pCR 67 adenocarcinomas 67 HER2 expression 67 nasopharyngeal carcinoma 67 basal cell nevus syndrome 67 diabetes mellitus DM 67 premalignant lesions 67 androgen deprivation 67 acute leukemias 67 locoregional recurrence 67 CC genotype 67 squamous cell carcinoma SCC 67 metastatic gastric 67 pT3 67 cutaneous melanoma 67 hepatic fibrosis 67 mutated K ras 67 pT2 67 oral squamous cell 67 testicular tumors 67 cervical lesions 67 malignant lymphoma 67 EGFR mutation positive 67 chlamydial infection 67 underwent resection 66 situ LCIS 66 chronic periodontitis 66 CP CPPS 66 endometrial hyperplasia 66 carotid stenosis 66 carotid plaques 66 cervical carcinoma 66 lung metastasis 66 leiomyomas 66 distant metastases 66 GISTs 66 Adjuvant chemotherapy 66 nonmelanoma skin cancer 66 curative resection 66 proliferative retinopathy 66 taxane therapy 66 polyp recurrence 66 TT genotype 66 mycosis fungoides 66 thyroid nodules 66 Papillary 66 adjuvant radiotherapy 66 cisplatin resistant 66 Waldenstrom macroglobulinemia 66 T1c 66 lobular breast cancer 66 leukemia AML 66 SSc 66 epithelial ovarian 66 HNPCC 66 thymoma 66 liver metastasis 66 radical prostatectomy RP 66 breast carcinomas 66 stage IIIb IV 66 haematologic 66 liver fibrosis 66 BRCA deficient 66 lymph node involvement 66 stage IIIA 66 prostate adenocarcinoma 66 metastatic lung cancer 66 NMIBC 66 renal carcinoma 66 intravesical therapy 66 renal cell carcinomas 66 metastatic renal cell carcinoma 66 colorectal adenomas 66 hepatocellular carcinoma HCC 66 neoplasm 66 hematopoietic cancers 66 metastatic RCC 65 chemoradiotherapy 65 node metastases 65 completely resected 65 PSADT 65 HGPIN 65 hormone receptor status 65 gastrointestinal stromal tumors GISTs 65 onset diabetes mellitus 65 BRCA mutation carriers 65 Hurthle cell 65 grade gliomas 65 macroalbuminuria 65 colorectal neoplasia 65 nodal metastases 65 proliferative diabetic retinopathy 65 lung carcinomas 65 esophageal cancers 65 bladder cancers 65 mucinous 65 HBeAg negative 65 transitional cell carcinoma 65 Chronic pancreatitis 65 hepatocellular carcinoma 65 IV NSCLC 65 EGFR mutations 65 lung adenocarcinoma 65 histologically confirmed 65 Surgical resection 65 osteosarcomas 65 pheochromocytoma 65 mesotheliomas 65 metachronous 65 Subgroup analysis 65 gefitinib Iressa 65 invasive carcinoma 65 nonseminoma 65 clinicopathological 65 nonalcoholic steatohepatitis NASH 65 Cholangiocarcinoma 65 lymph node metastasis 65 CYT# potent vascular disrupting 65 neoplastic lesions 65 perioperative morbidity 65 breast endometrial 65 gastrointestinal stromal tumor 65 urothelial bladder cancer 65 pancreatic lung 65 K ras mutations 65 seminomas 65 cell carcinomas 65 bladder carcinoma 65 bladder tumors 65 prognostic indicator 65 T2DM 65 non squamous NSCLC 65 HIV HCV coinfected 65 thyroid carcinoma 65 prognostic biomarker 65 obstructive coronary artery 65 metastatic bladder 65 PAOD 65 monoclonal gammopathy 65 KRAS mutation 65 pelvic lymphadenectomy 65 GIST tumors 65 hypermethylated 65 relapsed MM 65 gallstone disease 65 hormone receptor negative 65 progesterone receptor negative 65 antitumor effect 65 Hepatocellular Carcinoma HCC 65 lobular cancer 65 metastatic colorectal 65 pulmonary metastases 65 endometrial carcinoma 65 lymph node metastases 65 pituitary adenomas 65 cytoreduction 65 grade cervical intraepithelial 65 cholangiocarcinoma 65 fallopian tube carcinoma 64 neuroendocrine cancers 64 prognostic variables 64 lymphocytic leukemia 64 serum PSA 64 elevated triglyceride levels 64 carcinoid tumors 64 surgical debulking 64 orchitis 64 adenoma 64 renal tumors 64 localized renal 64 clinically detectable 64 IgA deficiency 64 anaplastic 64 neoadjuvant chemotherapy 64 colorectal adenocarcinoma 64 invasive lobular 64 uveal melanoma 64 lung adenocarcinomas 64 Sjögren syndrome 64 prostate pancreatic 64 hepatocellular cancer 64 primary hyperparathyroidism 64 malignant polyps 64 ductal breast cancer 64 gastric cancers 64 neuroblastoma tumors 64 SUVmax 64 prostate cancer CRPC 64 resectable 64 preoperative chemotherapy 64 CTEPH 64 biochemical relapse 64 ductal carcinomas 64 atrophic gastritis 64 metastatic malignant 64 peritoneal cancer 64 adjuvant radiation 64 MTHFR 64 peritoneal carcinomatosis 64 neoadjuvant therapy 64 autoantibody positive 64 tumor subtypes 64 tumors GIST 64 metaplasia 64 cervical intraepithelial neoplasia 64 advanced neoplasia 64 urine cytology 64 undergone radical prostatectomy 64 MALT lymphoma 64 metastatic prostate cancer 64 hormone refractory 64 estrogen receptor ER 64 chemoresistant 64 AAT deficiency 64 extracapsular extension 64 invasive lobular carcinoma 64 lymphadenectomy 64 nonalcoholic steatohepatitis 64 colorectal polyp 64 PCA3 gene 64 perimenopausal women 64 locoregional 64 NNRTI resistance 64 squamous histology 64 NAFLD 64 oesophageal adenocarcinoma 64 liver metastases 64 papillary carcinoma 64 Prognostic factors 64 castrate resistant prostate cancer 64 MYH9 gene 64 penetrance 64 nondiabetic patients 64 telomere lengths 64 pre malignant lesions 64 SCCHN 64 prognostic indicators 64 Hodgkin lymphoma HL 64 precancerous condition 64 acute myeloid 64 Doxil ® 64 microsatellite instability 64 hamartomas 64 BRCA1 mutations 64 trastuzumab Herceptin ® 64 cerebral infarction 64 CYP#D# genotype 64 pulmonary metastasis 64 coronary calcification 64 estrogen receptor negative 64 carcinoma HNSCC 64 latent celiac disease 64 ovarian malignancy 64 laryngeal cancer 64 colorectal neoplasms 64 carcinoids 64 colorectal polyps 64 heavily pretreated 64 cystectomy 64 SLNB 64 hsCRP levels 64 demonstrated antitumor activity 64 intestinal metaplasia 64 colorectal cancer 64 serum GGT 64 beta carotene supplementation 64 CaP 64 lymphoid tumors 64 ABCB1 64 refractory ovarian cancer 64 virological response 64 familial pancreatic cancer 64 GSTT1 64 paroxysmal AF 64 HER2 amplification 64 LHRH receptor positive 64 gastrointestinal cancers 63 immunocompetent 63 pancreatic carcinoma 63 lymphocytosis 63 osteopenic 63 proximal colon 63 TP# mutations 63 mCRC patients 63 cervical lymph nodes 63 systolic dysfunction 63 unresectable tumors 63 astrocytoma 63 basal cell carcinomas 63 hematologic toxicity 63 superficial bladder cancer 63 precancerous cervical 63 bronchogenic carcinoma 63 lichen planus 63 immunohistochemical staining 63 glycated hemoglobin levels 63 androgen deficiency 63 gastric cancer 63 invasive candidiasis 63 familial clustering 63 Squamous 63 TCF#L# 63 endothelial activation 63 distal colon cancer 63 Radical prostatectomy 63 EGFR mutation 63 juvenile idiopathic arthritis JIA 63 sarcomatoid 63 B7 H3 63 malignant prostate 63 prostate cancers 63 candidemia 63 metastatic lesions 63 intravenous bisphosphonates 63 preoperative PSA 63 breast pancreatic 63 BRCA2 mutations 63 decompensated cirrhosis 63 paragangliomas 63 MetS 63 pancreatic prostate 63 micrometastases 63 KRAS oncogene 63 INCB# [003] 63 metastatic malignant melanoma 63 pheochromocytomas 63 neoplasia 63 cranial irradiation 63 missense mutations 63 breast cancer metastasis 63 subclinical atherosclerosis 63 colorectal carcinomas 63 Medullary thyroid cancer 63 mutated KRAS 63 precancerous cervical lesions 63 Immunohistochemical staining 63 SHPT 63 parathyroid carcinoma 63 recurrent VTE 63 TTR amyloidosis 63 coinfected 63 VEGF expression 63 postoperative atrial fibrillation 63 advanced hepatocellular carcinoma 63 ASCUS 63 Endometrial 63 imatinib therapy 63 Gastric cancer 63 neurological manifestations 63 testicular cancers 63 recurrent metastatic 63 lymphoma subtypes 63 ovarian pancreatic 63 Leydig cell 63 rs# [004] 63 subclinical hyperthyroidism 63 esophageal adenocarcinoma 63 alpha1 antitrypsin deficiency 63 gastric cardia 63 diffuse gastric 63 KRAS status 63 adenocarcinoma 63 acute myelogenous leukemia AML 63 Gleevec resistant 63 resected pancreatic cancer 63 chromosomal aberrations 63 T1a 63 gastrointestinal stromal tumor GIST 63 stratifying patients 63 Haptoglobin 63 lymphomas leukemias 63 autonomic dysfunction 63 ovarian lung 63 specific antigen PSA 63 F FDG PET 63 leiomyoma 63 Clusterin 63 subclinical hypothyroidism 63 PHPT 63 ductal cancer 63 multivariate analyzes 63 stage IIIB IV 63 pegylated liposomal doxorubicin 63 RRM1 63 elevated LDH 63 castrate resistant 63 myeloproliferative disorder 63 sentinel lymph node biopsy 63 NSCLC tumors 63 neuroendocrine carcinoma 63 BRCA1 BRCA2 63 anthracycline containing 63 nonmelanoma 63 arterial thickening 63 Heavy menstrual bleeding 63 GBM tumors 63 histologic 63 ALA PDT 63 PROSTVAC VF 63 Chronic lymphocytic leukemia 63 Myelodysplastic syndromes MDS 63 familial adenomatous polyposis 63 vestibular schwannomas 63 HCV infection 63 minimally symptomatic 63 BRCA2 gene mutation 63 Gorlin syndrome 63 obstructive coronary 63 carcinoid tumor 63 node metastasis 63 hydroxyvitamin D levels 63 p# mutations 63 recurrent venous thromboembolism 63 promoter methylation 63 germline mutations 63 ovarian breast 63 follicular thyroid cancer 63 nonischemic 62 Hashimoto thyroiditis 62 CTAP# Capsules 62 nephron sparing surgery 62 postoperative AF 62 adrenocortical cancer 62 hyperplastic polyps 62 prognostic significance 62 recurrent NSCLC 62 malignancies 62 breast cancer subtypes 62 secondary hyperparathyroidism 62 recurrent ovarian cancer 62 colorectal gastric 62 autoimmune pancreatitis 62 BRAF V#E 62 malignant neoplasms 62 paraganglioma 62 spontaneously regress 62 Adenomas 62 adenomatous 62 liver transplant recipients 62 thrombophilia 62 carotid IMT 62 surgically resectable 62 KRAS mutations 62 medullary thyroid cancer 62 neoplastic 62 dysglycemia 62 AGHD 62 metastatic neuroendocrine tumors 62 recurrent UTI 62 squamous cell cancers 62 APOL1 62 colorectal lung 62 hyperplastic 62 multivariate Cox 62 colonic polyps 62 endocrine therapies 62 postoperative morbidity 62 cyclin E 62 gene polymorphism 62 leukemia ALL 62 myeloproliferative diseases 62 Glioblastoma Multiforme GBM 62 PGDH 62 follicular lymphoma FL 62 imatinib resistant 62 tumorigenicity 62 oligodendrogliomas 62 malignant pheochromocytoma 62 adjuvant therapies 62 smoldering myeloma 62 LV dysfunction 62 transferrin saturation 62 BRAF mutations 62 gynecologic malignancy 62 p# biomarker 62 androgen ablation 62 chronic hepatitis cirrhosis 62 tumor subtype 62 coinfection 62 situ CIS 62 aminotransferases 62 Basal cell 62 small lymphocytic lymphoma 62 TRAIL R1 62 hepatorenal syndrome 62 neovascular 62 metastatic lymph nodes 62 nondiabetic 62 chemopreventive agent 62 BRCA mutations 62 metastatic renal 62 colorectal cancer incidence 62 atherosclerotic lesions 62 myeloperoxidase 62 urolithiasis 62 antigen PSA 62 juvenile idiopathic arthritis 62 recurrent acute pancreatitis 62 adenocarcinoma histology 62 HER2 amplified 62 KRAS wild 62 squamous cell histology 62 dopaminergic therapy 62 cytoreductive surgery 62 pleural mesothelioma 62 histological subtypes 62 univariate analyzes 62 multivariable analysis 62 inflammatory rheumatic 62 neoplastic cells 62 EBV infection 62 CIN2 62 PTPN# 62 narcolepsy cataplexy 62 allogeneic HSCT 62 colon rectal 62 seminal vesicle invasion 62 BRCA2 mutation carriers 62 #.#ng/ml 62 choroidal neovascularization 62 NSCLC 62 albumin excretion rate 62 coronary stenosis 62 thromboembolic disease 62 CVD mortality 62 abnormal cytology 62 malignant growths 62 #F FDG PET 62 seropositivity 62 familial hypercholesterolemia FH 62 motor neuron degeneration 62 GBA mutations 62 overt nephropathy 62 PCA3 scores 62 xenograft tumors 62 acute lymphoblastic 62 recurrent endometrial cancer 62 resistant hormone refractory 62 TOP2A 62 intestinal polyps 62 PARP inhibition 62 bronchopulmonary dysplasia 62 oral Hycamtin 62 invasive aspergillosis 62 ano genital warts 62 essential thrombocythemia 62 debulking surgery 62 elevated CRP 62 posttransplant 62 diagnostic biomarker 62 hereditary predisposition 62 chromosomal mutations 62 underwent radical prostatectomy 62 BRAF V#E mutation 62 Chronic Myelogenous Leukemia CML 62 colorectal liver metastases 62 relapsed ovarian cancer 62 transurethral resection 62 lymphoproliferative disorders 62 intima media thickness 62 prognostic markers 62 confidence interval #.#-#.# 62 heterozygotes 62 deCODE BreastCancer TM 62 recurrent ovarian 62 APOE ε4 62 serum urate levels 62 bullous 62 ischemic lesions 62 EGFR tyrosine kinase inhibitors 62 thromboembolic complications 62 myeloproliferative neoplasms 62 elevated IOP 62 mitochondrial toxicity 62 epithelial cancers 62 carcinoid 62 postoperative complication 62 coronary artery aneurysms 62 benign moles 62 renal cell carcinoma 62 paricalcitol 62 familial aggregation 62 CLL SLL 62 anthracycline taxane 62 nonhereditary 62 Barrett esophagus 62 urinary bladder cancer 62 axillary lymph nodes 62 thromboembolic events 62 esophageal gastric 62 neurocognitive function 62 squamous cell cancer 62 Renal Cell Carcinoma RCC 62 Anaplastic 62 ductal adenocarcinoma 62 C. trachomatis 62 severe periodontitis 62 mRCC 62 Adjuvant therapy 62 solar keratosis 62 antihypertensive therapy 62 tumor xenograft models 62 clinicopathologic 62 genotypic resistance 62 histologically proven 62 #q#.# [001] 62 Colon polyps 62 multiple myeloma MM 62 pharyngeal cancer 62 elevated serum creatinine 62 hepatoma 62 Glioblastoma Multiforme 61 malignant pancreatic 61 brain lesions 61 GH deficiency 61 squamous cell 61 refractory prostate cancer 61 malignant brain 61 grade cervical dysplasia 61 thiopurine 61 ALND 61 rectal cancers 61 alanine aminotransferase ALT 61 thyroid carcinomas 61 astrocytomas 61 rs# [002] 61 anemia hemoglobin 61 cancerous enlargement 61 FDG uptake 61 bronchoalveolar lavage 61 underwent surgical resection 61 chronic myeloid 61 Subgroup analyzes 61 HSCT 61 malignant ascites 61 Pneumocystis carinii pneumonia 61 cell carcinoma 61 DLBCL 61 atopic asthma 61 spontaneous preterm delivery 61 carcinoma 61 thrombocytopenic 61 K ras gene 61 renal cysts 61 MSH2 61 familial ALS 61 GNAQ 61 myelofibrosis polycythemia vera 61 prognostic factor 61 leukaemias 61 total thyroidectomy 61 comorbid depression 61 urate levels 61 radiosensitivity 61 neurodevelopmental outcome 61 SRBD 61 nutlin 3a 61 adrenalectomy 61 HER2 positive breast cancer 61 metastatic renal cell 61 BCG refractory 61 noncardiac 61 subependymal giant cell 61 neoplasms 61 castration resistant 61 neurocognitive impairment 61 aortic atherosclerosis 61 axillary dissection 61 multivessel disease 61 graft dysfunction 61 lactate dehydrogenase 61 Actinic Keratosis 61 GSTP1 61 flutamide 61 Nilotinib 61 colorectal cancers 61 indolent lymphomas 61 bacteriuria 61 Adenocarcinoma 61 Hematologic 61 normal karyotype 61 pancreatic NET 61 amnestic MCI 61 genetic polymorphisms 61 serum biomarkers 61 metastatic prostate 61 chromosomal alterations 61 prostate carcinogenesis 61 basal cell cancers 61 carotid atherosclerosis 61 etiologic 61 external genital lesions 61 prostatic adenocarcinoma 61 idiopathic PAH 61 liposomal amphotericin B 61 lenalidomide dexamethasone 61 lung cancer NSCLC 61 benign breast 61 relapsed AML 61 metastases 61 PSA nadir 61 undergoing radical prostatectomy 61 nonischemic cardiomyopathy 61 mutated KRAS gene 61 metastatic GIST 61 Leukemias 61 sporadic ALS 61 FLT3 mutations 61 Aortic stenosis 61 B Cell Lymphoma 61 Metastases 61 p# biomarkers 61 hypervascular 61 tumor necrosis 61 intra abdominal abscess 61 coagulation disorders 61 fulminant hepatic failure 61 median survivals 61 ductal lobular 61 H. pylori eradication 61 antigen PSA levels 61 benign prostatic hypertrophy BPH 61 SHBG levels 61 β blockers 61 lung tumors 61 R0 resection 61 vulvar intraepithelial neoplasia 61 adrenocortical 61 IV melanoma 61 genetic determinants 61 bardoxolone methyl 61 radiotherapy RT 61 parathyroid 61 lung carcinoma 61 Synovial sarcoma 61 amnestic mild cognitive impairment 61 Helicobacter pylori eradication 61 LVNC 61 contralateral breast 61 QTc prolongation 61 leukocyte count 61 proband 61 telomerase inhibition 61 autoimmune thyroid 61 K ras mutation 61 unresectable 61 albumin excretion 61 fibroadenomas 61 antiphospholipid antibodies 61 infarcts 61 imatinib resistance 61 HbF 61 endometrioid 61 BRAF mutation 61 leukemias lymphomas 61 NAT2 61 antiproliferative effects 61 hormone deprivation 61 androgenic alopecia 61 familial hypercholesterolemia 61 diabetic nephropathy 61 radiochemotherapy 61 basal cell skin 61 myelodysplastic syndrome MDS 61 severe oral mucositis 61 CMV disease 61 cell lymphoma CTCL 61 keloid scarring 61 chorioamnionitis 61 immunohistochemical 61 clinico pathological 61 lymphangiogenesis 61 epithelioid 61 invasive ductal breast cancer 61 severe neutropenia 61 bladder ovarian 61 ERBB2 61 soft tissue sarcomas 61 cirrhotic 61 noscapine 61 antiangiogenic therapy 61 untreated celiac disease 61 sustained virological response 61 pentoxifylline 61 Prostatitis 61 BRCA1 mutation carriers 61 retrospective cohort 61 LHRH agonists 61 vWD 61 BCR ABL mutations 61 axillary node dissection 61 intracranial stenosis 61 nondemented 61 liposomal doxorubicin 61 prednisone prednisolone 61 IFN beta 61 receptor inhibitor 61 adenoma recurrence 61 sCJD 61 Barrett esophagus BE 61 Alequel 61 Non inferiority 61 microRNA expression 61 prostate carcinomas 61 Zavesca R 61 beta blocker therapy 61 hypercholesterolemic patients 61 acute promyelocytic leukemia APL 61 metastatic basal cell 61 myeloablative 61 atherosclerotic disease 61 endometrial cancer 61 multivariable adjusted 61 abacavir Ziagen 61 chronic GVHD 61 thyroglobulin 61 systemic amyloidosis 61 LRP5 61 bone metastasis 61 carcinomas 61 metastatic pancreatic 61 rs# [001] 61 scintigraphic 61 SNP rs# [001] 61 esophageal carcinoma 61 thyrotropin 61 serum estradiol 61 chronic HBV infection 61 recurrent prostate cancer 61 SNP rs# [002] 61 cardiac repolarization 61 K ras 61 rebleeding 61 baseline LDH 61 eosinophil count 61 clinicopathological features 61 Amrubicin 61 alkylating agent 61 WT1 61 lung metastases 61 BCG vaccinated 61 mycophenolate mofetil 61 AA Amyloidosis 61 AML MDS 61 ependymoma 61 neoadjuvant radiation 61 genomic biomarker 61 SORT OUT III 61 histologies 61 micafungin 61 squamous 61 locoregional disease 61 hepatic metastases 61 kidney urologic 61 intensive statin therapy 61 rheumatic disease 61 postoperative mortality 61 localized prostate 61 tumoral 61 histologic subtypes 61 non alcoholic steatohepatitis 61 micronuclei 61 UVB induced 61 amyloid deposition 61 antiestrogen 61 thalidomide Thalomid 61 pediatric acute lymphoblastic 61 cinacalcet 61 Hyperlipidemia 61 alpha1 antitrypsin AAT deficiency 61 Circulating tumor cells 61 1 diabetes T1D 61 subclinical disease 61 Asymptomatic 61 ALI ARDS 61 esophagogastric junction 61 systemic lupus erythematosus SLE 61 pancreatic neuroendocrine tumors 61 Candida infection 61 disease progression 61 Brain metastases 61 axillary node 61 relapsing remitting MS RRMS 61 lymphocytic 61 spontaneous regression 60 promoter hypermethylation 60 ADAMTS# 60 malignant lymphomas 60 Severe Primary IGFD 60 sustained ventricular tachycardia 60 supratentorial 60 radioiodine therapy 60 thrombocytosis 60 CMV infections 60 cerebral vasospasm 60 troponin T 60 cytokeratin 60 atypia 60 ovulatory cycles 60 systemic lupus erythematosus 60 salmeterol HFA MDI 60 radical retropubic prostatectomy 60 arterial calcification 60 Rectal cancer 60 polycystic ovarian syndrome PCOS 60 Microalbuminuria 60 malignancy 60 postoperative delirium 60 antibody titer 60 Her2/neu 60 Toxicities 60 Nicotine dependence 60 artery stenosis 60 complete cytogenetic response 60 androgenetic alopecia 60 Kaposi sarcoma 60 carcinoembryonic antigen 60 gestational diabetes mellitus 60 virologic response 60 medulloblastomas 60 TGFBR1 * 6A 60 benign prostatic hypertrophy 60 pulmonary dysfunction 60 HIVAN 60 aminotransferase levels 60 neoadjuvant 60 precancers 60 transthyretin amyloidosis 60 bilateral oophorectomy 60 Chlamydia trachomatis infection 60 invasive breast cancer 60 MGd 60 thyrotoxicosis

Back to home page